William Blair Investment Management LLC Has $13.10 Million Holdings in PROCEPT BioRobotics Corporation $PRCT

William Blair Investment Management LLC lifted its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 8.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 416,243 shares of the company’s stock after acquiring an additional 33,226 shares during the quarter. William Blair Investment Management LLC’s holdings in PROCEPT BioRobotics were worth $13,095,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Alliancebernstein L.P. lifted its holdings in PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after purchasing an additional 1,262,928 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in PROCEPT BioRobotics by 23.3% during the third quarter. Westfield Capital Management Co. LP now owns 1,970,147 shares of the company’s stock worth $70,315,000 after purchasing an additional 371,798 shares during the period. Mackenzie Financial Corp grew its holdings in PROCEPT BioRobotics by 105.2% during the third quarter. Mackenzie Financial Corp now owns 1,454,434 shares of the company’s stock valued at $51,909,000 after purchasing an additional 745,778 shares during the last quarter. Champlain Investment Partners LLC raised its position in shares of PROCEPT BioRobotics by 34.3% in the third quarter. Champlain Investment Partners LLC now owns 1,437,897 shares of the company’s stock valued at $51,319,000 after purchasing an additional 367,251 shares during the period. Finally, Artisan Partners Limited Partnership lifted its stake in shares of PROCEPT BioRobotics by 38.4% in the third quarter. Artisan Partners Limited Partnership now owns 1,365,099 shares of the company’s stock worth $48,720,000 after buying an additional 378,844 shares during the last quarter. 89.46% of the stock is owned by institutional investors.

Insider Transactions at PROCEPT BioRobotics

In other news, Director Antal Rohit Desai bought 167,246 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average cost of $25.58 per share, with a total value of $4,278,152.68. Following the completion of the transaction, the director directly owned 167,246 shares in the company, valued at $4,278,152.68. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Waters sold 6,721 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $23.70, for a total value of $159,287.70. Following the transaction, the executive vice president owned 152,264 shares in the company, valued at $3,608,656.80. This represents a 4.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have purchased 426,262 shares of company stock worth $10,483,091 and have sold 23,229 shares worth $573,466. Insiders own 6.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Tuesday, April 21st. Robert W. Baird initiated coverage on shares of PROCEPT BioRobotics in a research report on Friday, March 6th. They set a “neutral” rating and a $30.00 target price for the company. Truist Financial decreased their price target on shares of PROCEPT BioRobotics from $47.00 to $30.00 and set a “buy” rating for the company in a report on Friday, February 27th. Leerink Partners dropped their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Finally, Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $41.45.

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock opened at $29.00 on Tuesday. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $66.85. The company’s fifty day simple moving average is $25.45 and its 200-day simple moving average is $28.62. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -15.93 and a beta of 0.83. The company has a current ratio of 6.73, a quick ratio of 5.51 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $80.52 million. During the same quarter in the previous year, the company earned ($0.45) earnings per share. PROCEPT BioRobotics’s revenue for the quarter was up 20.1% compared to the same quarter last year. As a group, sell-side analysts expect that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.